Inovio Pharmaceuticals (INO) Corporate Presentation summary

Strategic focus and financial position

• Developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, with a deep clinical pipeline and multiple near- and mid-term catalysts.

• $68.4M in cash, cash equivalents, and short-term investments as of March 31, 2025.

• Established commercial-scale manufacturing for plasmids and in-house device production.

• Lead program INO-3107 targets Recurrent Respiratory Papillomatosis (RRP), with BLA submission planned for mid-2025 and potential launch in 2026.

• Next-generation therapeutics and vaccines in earlier development stages aim to expand the platform's potential.

Clinical pipeline and lead programs

• INO-3107 for RRP is in registrational stage, granted Orphan Drug and Breakthrough designations in the US and EU.

• INO-3112 targets HPV-related throat cancer, with a Phase 3 trial planned in collaboration with Coherus Biosciences.

• INO-5401 for glioblastoma completed Phase 1/2 trial, showing favorable tolerability and immunogenicity.

• Additional candidates include DMAb (DNA-encoded monoclonal antibodies), DPROTS (protein replacement), and DLNPs (vaccines for COVID-19, HIV, and other diseases).

• Out-licensed programs include VGX-3100 for cervical dysplasia and INO-4800 for COVID-19 in China.

INO-3107 clinical data and market potential

• Phase 1/2 trial in RRP showed 72% overall response rate at 52 weeks, improving to 86% at 104 weeks.

• Mean surgeries per year reduced from 4.1 pre-treatment to 0.9 at 104 weeks and 0.8 at 156 weeks.

• Well-tolerated safety profile, with most adverse events being mild and no discontinuations.

• Immunology data showed robust antigen-specific T cell responses correlating with clinical benefit.

• Market research indicates strong physician preference for efficacy, tolerability, and office-based administration.